Last €57.21 EUR
Change Today -0.24 / -0.42%
Volume 9.4K
TUB On Other Exchanges
EN Brussels
EN Brussels
As of 11:35 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

financiere de tubize (TUB) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/28/14 - €63.21
52 Week Low
04/11/14 - €47.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for FINANCIERE DE TUBIZE (TUB)

Related News

No related news articles were found.

financiere de tubize (TUB) Related Businessweek News

No Related Businessweek News Found

financiere de tubize (TUB) Details

Financiere de Tubize SA/NV, through its equity interest in UCB SA, engages in the research, development, and commercialization of pharmaceutical products primarily in the therapeutic areas of central nervous system (CNS) and immunology disorders worldwide. Its CNS products include Keppra, which is used to treat partial onset seizures in adults, children, and infants; Neupro for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease, as well as idiopathic restless legs syndrome in adults; Metadate CD to treat attention deficit hyperactivity disorder; Nootropil to treat vertigo and events associated with ageing; Xyrem, a sodium oxybate drug for narcolepsy with cataplexy in adult patients; and Vimpat indicated for partial-onset seizures. The company’s immunology disorder products comprise Cimzia to treat Crohn’s disease and rheumatoid arthritis; Xyzal for treating allergic rhinitis, including persistent allergic rhinitis and chronic idiopathic urticaria; Zyrtec, an antihistamine for the symptomatic treatment of seasonal allergic rhinitis, perennial rhinitis, and chronic idiopathic urticaria; Tussionex for relief of cough and upper respiratory symptoms; and Lortab for the relief of severe pain. It also offers other products, including BUP-4 for urinary incontinence; Deponit, Isoket, and Perlinganit solution for coronary heart disease; Edex/Viridal for erectile dysfunction; Elantan, a long-term treatment of coronary artery disease; Ferro Sanol for iron and folic deficiency; Nipruss for hypertensive crisis and controlled intra-operative hypotension; Prostavasin for treating peripheral arterial occlusive disease; Stogar for digestive disorders; and Uniretic/Femipres Plus/Perdix Plus and Univasc/Femipres/Perdix for treating hypertension. Financiere de Tubize SA/NV is based in Brussels, Belgium.

financiere de tubize (TUB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

financiere de tubize (TUB) Key Developments

Financière De Tubize S.A. Announces Consolidated and Non-Consolidated Earnings Results for the First Half of 2014

Financière de Tubize S.A. announced consolidated and non-consolidated earnings results for the first half of 2014. On consolidated the, the company reported profit of EUR 41.4 million. On non-consolidated the, the company reported profit of EUR 64.1 million.

Financière de Tubize Announces Unaudited Consolidated Earnings Results for the Fiscal Year 2013

Financière de Tubize announced unaudited consolidated earnings results for the fiscal year 2013. For the year, operating loss was EUR 813,000 against EUR 534,000 a year ago. Profit for the year before taxes was EUR 56,683,000 against EUR 54,177,000 a year ago. Profit for the year was EUR 56,683,000 against EUR 54,177,000 a year ago.

Financière de Tubize S.A. to Approve Dividend for the Year 2013, Payable on May 7, 2014

Financière de Tubize S.A. announced that the shareholders at the general shareholders meeting to be held on April 23, 2014 will consider and approve gross dividend of EUR 0.48 per share for the year 2013 will be payable as from 7 May 2014 onwards at the offices, seats and branches of BNP Paribas Fortis, in exchange of coupon n° 9. The ex-date is May 2, 2014 and record date is May 6, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TUB:BB €57.21 EUR -0.24

TUB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TUB.
View Industry Companies

Industry Analysis


Industry Average

Valuation TUB Industry Range
Price/Earnings 23.8x
Price/Sales -- Not Meaningful
Price/Book 1.4x
Price/Cash Flow 23.8x
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FINANCIERE DE TUBIZE, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at